5:32 PM
 | 
Dec 19, 2012
 |  BC Extra  |  Company News

NeRRe debuts with L11.5 million

NeRRe Therapeutics Ltd. (Stevenage, U.K.) debuted on Wednesday to develop a pipeline of four clinical and preclinical neurokinin receptor antagonists from GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), which has an undisclosed...

Read the full 130 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >